Novartis's Share Strength Sets High Expectations for Clinical Pipeline Data

Novartis's strong share price this year raises expectations for its late-stage clinical studies. Success would help shift investor sentiment, while failure could impact consensus estimates. The Swiss drugmaker's pipeline is crucial for its outlook.